All In Biotech

Drug Trial Radar · NCT06662786

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Oct 18, 2024

Primary completion

Dec 15, 2028

Study completion Jan 20, 2032

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.

Conditions

  • Colorectal Neoplasms

Interventions

  • AmivantamabBiological

    Amivantamab will be administered.

  • CetuximabBiological

    Cetuximab will be administered.

  • 5-fluorouracilDrug

    5-fluorouracil will be administered as chemotherapy regimen.

  • Leucovorin calcium/LevoleucovorinDrug

    Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.

  • OxaliplatinDrug

    Oxaliplatin will be administered as chemotherapy regimen.

  • Irinotecan HydrochlorideDrug

    Irinotecan hydrochloride will be administered as chemotherapy regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to 4 years and 2 months

Locations

239 sites in 22 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • St. Bernard's Medical Center

    Jonesboro, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • CBCC Global Research

    Bakersfield, California · Recruiting

  • Los Angeles Cancer Network

    Glendale, California · Recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UCLA

    Santa Monica, California · Recruiting

  • Providence Medical Foundation

    Santa Rosa, California · Recruiting

  • Torrance Memorial Physicians Network

    Torrance, California · Recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Recruiting

  • Yale University School Of Medicine

    New Haven, Connecticut · Recruiting

  • Georgetown Univ Medical Center Lombardi Cancer Center

    Washington D.C., District of Columbia · Recruiting

  • Florida Cancer Specialists South

    Fort Myers, Florida · Recruiting

  • AdventHealth Medical Group Oncology and Hematology at Orlando

    Orlando, Florida · Recruiting

  • Florida Cancer Specialists North Region

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists East

    West Palm Beach, Florida · Recruiting

  • Grady Memorial Hospital

    Atlanta, Georgia · Recruiting

  • Winship Cancer Institute Emory University

    Atlanta, Georgia · Recruiting

  • Illinois Cancer Specialists

    Arlington Heights, Illinois · Recruiting

  • Illinois CancerCare

    Peoria, Illinois · Recruiting

  • Fort Wayne Medical Oncology & Hematology

    Fort Wayne, Indiana · Recruiting

  • University of Iowa Hospital

    Iowa City, Iowa · Recruiting

  • Mission Cancer Blood

    Waukee, Iowa · Recruiting

  • Cancer Center of Kansas

    Wichita, Kansas · Recruiting

  • Ochsner Clinic Foundation

    New Orleans, Louisiana · Recruiting

  • MedStar Franklin Square Medical Center

    Baltimore, Maryland · Recruiting

  • Frederick Health Hospital - James M Stockman Cancer Institute

    Frederick, Maryland · Recruiting

  • VA Ann Arbor Healthcare System

    Ann Arbor, Michigan · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Cancer And Hematology Centers of Western Michigan PC

    Grand Rapids, Michigan · Recruiting

  • Hattiesburg Clinic

    Hattiesburg, Mississippi · Recruiting

  • Washington University School Of Medicine

    St Louis, Missouri · Recruiting

  • Nebraska Cancer Specialists Midwest Cancer Center

    Omaha, Nebraska · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada · Recruiting

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

  • Rutgers Cancer Institute

    New Brunswick, New Jersey · Recruiting

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico · Recruiting

  • Perlmutter Cancer Center at NYU Long Island

    Mineola, New York · Recruiting

Showing 40 of 239 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.